eddie pharmaceutical (688488) 0.204 billion restricted shares will be lifted on July 20, accounting for 48.63 of the total share capital

According to public market information, Eddy Pharmaceutical (688488) lifted the ban on the listing of 0.204 billion restricted shares on July 20, which was the company's first original shareholder restricted shares, accounting for 48.63 of the company's total share capital. In the past year, 2.8592 million shares have been lifted, accounting for 0.68 per cent of the total share capital. After the lifting of the ban, the company has unlimited shares to sell. As shown in the following figure:

See the following table for details of shareholders involved in this lifting of the ban:

Eddie's financial data and main business:

eddie pharmaceutical's 2023 quarterly report showed that the company's main revenue was 0.113 billion yuan, up 220.85 from the same period of last year. Net profit attributable to the parent was 486200 yuan, up 102.18 from the same period of last year. Deduction of non-net profit -5.4495 million yuan, up 79.55 from the same period of last year; Debt ratio 29.17, investment income 4.0797 million yuan, financial expenses 1.8552 million yuan, gross profit margin 44.32.

Eddie Pharmaceuticals (688488) main business: focus on the pharmaceutical field, set drug research and development, production, sales in one.

The above content is compiled by Securities Star based on publicly available information, generated by an algorithm, and has nothing to do with the position of this site. Securities Star strives for but does not guarantee the accuracy, completeness, validity, timeliness, etc. of all or part of the information (including but not limited to text, video, audio, data and charts). If there is any problem, please contact us. This article is a data compilation, does not constitute any investment advice for you, investment is risky, please be cautious in your decision-making.